| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b08331191edf52b8907dd1b18d355982 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2513-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2306 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 |
| filingDate |
2020-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81d27eb9d8e6d704d8224129b9ab7552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_400a3d3c7e14ce649e09b5b87cc58856 |
| publicationDate |
2021-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021052641-A1 |
| titleOfInvention |
Pre-conditioned extracellular vesicles and methods of production |
| abstract |
A method for treating inflammatory diseases is provided. The method may include administering to a subject in need thereof a therapeutically effective amount of isolated extracellular vesicles or exosomes obtained from mesenchymal stem cells pre-conditioned with at least TNF-α. The isolated extracellular vesicles or exosomes may exhibit (a) enhanced expression of flotillin-1, (b) enhanced expression of CD73, or (c) enhanced expression of IDO. A method of isolating extracellular vesicles or exosomes capable of treating an inflammatory disease is also provided, wherein the method may include (a) culturing stem cells in a growth medium, (b) then culturing the stem cells in a starve medium supplemented with at least TNF-α, and (c) separating exosomes or extracellular vesicles from the culture. Cultures suitable for treatment are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114306732-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115707336-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115161276-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115354022-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114395609-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11613734-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022396771-A1 |
| priorityDate |
2019-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |